scorecardresearch
Wednesday, August 13, 2025
TopicBharat Biotech

Topic: Bharat Biotech

After final analysis, Bharat Biotech announces an efficacy of 77.8% of Covaxin

The Hyderabad-based company claims that the efficacy data demonstrates 63.6 per cent protection against asymptomatic Covid-19.

Brazil-Bharat Biotech’s $324 million contract suspended: What went wrong in the Covaxin deal

Brazil Tuesday suspended its deal with Bharat Biotech for 20 million Covaxin doses amid an ongoing investigation into alleged irregularities & corruption. ThePrint gives you the details.

Covaxin effectively neutralises both Delta & Alpha variants of Covid, US NIH studies find

Interim results from the phase 3 trial indicate that Covaxin has 78% efficacy against symptomatic disease & 100% efficacy against severe Covid, including hospitalisation, NIH said.

Covaxin phase 3 trial data showing ‘77.8% efficacy’ reviewed by expert panel. Over to DCGI

Subject Expert Committee, which advises DCGI on approvals for new drugs & vaccines. has not yet discussed changing the status of Covaxin from emergency use to full licensure.

Final verdict on Covaxin efficacy could come soon as Bharat Biotech submits phase 3 trial data

Bharat Biotech submitted phase 3 trial data of Covaxin to the Drug Controller General of India. The data is crucial to ascertaining the efficacy of a vaccine.

WHO accepts Bharat Biotech’s expression of interest for Covaxin

A pre-submission meeting with WHO will take June 23 during which the vaccine maker will have an opportunity to submit a summary on the overall quality of the jab.

Complex manufacturing, R&D, risks, losses — Bharat Biotech explains why Covaxin is expensive

Bharat Biotech also says Rs 150 per dose price for the government is 'non-competitive' and not sustainable in the long run.

Covaxin supply price to Centre at Rs 150/dose not sustainable in long run: Bharat Biotech

Bharat Biotech said reasons such as low procurement volumes, high distribution costs and retail margins among others contribute to the higher pricing of Covaxin.

Recruitment for Covaxin clinical trials in 6-12 age group to start at AIIMS from 15 June

The Drugs Controller General of India had granted permission for conducting the phase 2/3 clinical trial of Bharat Biotech's Covaxin among children aged two to 18 years on 12 May.

On Camera

Asim Munir wants to be guardian of the Middle East. He’s fated to fail at home

Countering insurgency needs the Pakistan Army to demonstrate a political will that ties leaders at the centre with those in the borderlands. But it may not have the imagination.

Slashing GST on waste can unlock Rs 1.8 lakh crore, high tax hurting circular economy goals—CSE

Centre for Science and Environment in new report makes case for rationalising GST on waste material, saying most informal operators can’t afford high tax & it also hinders recycling.

India, US troops to undertake joint military exercise next month, first after Op Sindoor

21st edition of annual joint military exercise will be held from 1 to 16 September, aimed at sharing military tech, operational best practices & disaster relief coordination methods.

Modi’s ready to risk it all for farmers. Farm reform can answer Trump with new Green Revolution

Standing up to America is usually not a personal risk for a leader in India. Any suggestions of foreign pressure unites India behind who they see as leading them in that fight.